Muscle uncoupling protein 3 expression is unchanged by chronic ephedrine/caffeine treatment : results of a double blind, randomised clinical trial in morbidly obese females by R. Bracale et al.
Muscle Uncoupling Protein 3 Expression Is Unchanged
by Chronic Ephedrine/Caffeine Treatment: Results of a
Double Blind, Randomised Clinical Trial in Morbidly
Obese Females
Renata Bracale1, Maria Letizia Petroni2, Sergio Davinelli1,3, Umberto Bracale4, Giovanni Scapagnini1,3,
Michele O. Carruba5, Enzo Nisoli5*
1Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, 2Clinical Nutrition Laboratory, IRCCS Institute Auxologico Italiano, Piancavallo
(Verbania), Italy, 3 Inter-University Consortium ‘‘SannioTech’’, Benevento, Italy, 4Department of Public Health, University of Naples ‘‘Federico II’’, Naples, Italy, 5Center for
Study and Research on Obesity, Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Abstract
Ephedrine/caffeine combination (EC) has been shown to induce a small-to-moderate weight loss in obese patients. Several
mechanisms have been proposed, among which an increased thermogenic capacity of skeletal muscle consequent to the
EC-induced up-regulation of uncoupling protein 3 (UCP3) gene expression. We did a parallel group double-blind, placebo-
controlled, 4-week trial to investigate this hypothesis. Thirteen morbidly obese women (25–52 years of age, body-mass
index 48.064.0 kg/m2, range 41.1–57.6) were randomly assigned to EC (200/20 mg, n = 6) or to placebo (n = 7) administered
three times a day orally, before undergoing bariatric surgery. All individuals had an energy-deficit diet equal to about 70% of
resting metabolic rate (RMR) diet (mean 576961105 kJ/day). The RMR analysed by intention to treat and the UCP3 (long and
short isoform) mRNA levels in rectus abdominis were the primary outcomes. Body weight, plasma levels of adrenaline,
noradrenaline, triglycerides, free fatty acids, glycerol, TSH, fT4, and fT3 were assessed, as well as fasting glucose, insulin and
HOMA index, at baseline and at the end of treatments. Body weight loss was evident in both groups when compared to
baseline values (overall 25.263.2%, p,0.0001) without significant differences between the treated groups. EC treatment
increased the RMR (+9.266.8%, p = 0.020), differently from placebo which was linked to a reduction of RMR (27.666.5%,
p = 0.029). No significant differences were seen in other metabolic parameters. Notably, no changes of either UCP3 short or
UCP3 long isoform mRNA levels were evident between EC and placebo group. Our study provides evidence that 4-week EC
administration resulted in a pronounced thermogenic effect not related to muscle UCP3 gene expression and weight loss in
morbidly obese females under controlled conditions.
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Introduction
Ephedrine and caffeine (EC) combination has been widely used
in human obesity treatment [1,2], and is still present in many
herbal preparations sold widespread in many countries for weight
loss. It is well known that this drug increases the metabolic rate in
both animals and humans [3,4]. Ephedrine is an agonist of both a-
and b-adrenoceptors; moreover, it induces noradrenaline release
from sympathetic neurons, and thus it is a sympatho-mimetic drug
with a mixed profile [5]. Caffeine increases both noradrenaline
and dopamine release and stimulates the neuronal activity in
several brain regions. In addition, caffeine antagonizes the
inhibitory effects of adenosine on sympathetic nervous system
(SNS). This modulation of SNS activity may be a possible
explanation for the thermic effect of EC [6,7]. In fact,
noradrenaline activates the uncoupling protein 1 (UCP1), a
member of mitochondrial carriers localized on the inner
mitochondrial membrane in brown adipocytes [8]. The physio-
logical role of UCP1 is to uncouple oxidative phosphorylation,
therefore most of the energy is dissipated as heat rather than being
converted to ATP [9].
In addition to UCP1, expressed exclusively in brown adipose
tissue (BAT), where it plays an important role in adaptive
thermogenesis and energy expenditure in rodents and possibly in
humans [10,11], two other members of the mitochondrial anion
carrier protein family play important physiological role. UCP2 is
widely expressed in human tissues, including skeletal muscle, fat,
heart, placenta, lung, liver, kidney, and pancreas, where it is
involved in the control of radical oxygen species (ROS) production
[12,13]. UCP3 is expressed almost exclusively in skeletal muscle
[14] and although its function is still not clearly established, therein
it would be involved in decreasing ROS production and
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promoting muscle fatty acid oxidation [15]. Unlike UCP1 and
UCP2, the UCP3 exhibits two transcriptional isoforms: a long
form (UCP3L) and a short form (UCP3S). Clapham et al. [16]
showed that transgenic mice overexpressing UCP3 were lean,
despite the fact that they were hyperphagic, in comparison to their
wild-type littermates. The 66-fold up-regulation of UCP3 mRNA
in skeletal muscle was linked to improved glucose tolerance,
decreased fasting blood glucose and insulin levels, 25% increase in
resting oxygen consumption, decreased total cholesterol, decreased
fasting blood glucose and insulin levels, and a 44% to 57%
reduction in adipose tissue over total animal volume [16].
Moreover, 5 days on caloric restriction resulted in ,2- to 3-fold
increase of the UCP3 mRNA levels in lean and obese humans
[17], and caffeine upregulates UCP3 expression in skeletal muscle,
which was suggested to contribute to thermogenesis in obese
yellow KK mice [18]. Aims of the present work were to investigate
changes in energy expenditure and UCP3 expression in skeletal
muscle of morbidly obese females treated with either placebo or
EC.
Materials and Methods
Ethics Statement
The trial was done in accordance with the Declaration of
Helsinki and ICH Good Clinical Practice. The protocol was
approved by Istituto Auxologico Italiano and Regione Piemonte
(Italy) Institutional Review Boards, and participants provided
written informed consent. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1. The trial started
(first patient enrolled) in February 2000 and ended (last patient
completed the clinical study) in January 2001. The study was not
registered in a Clinical Trial Registry since enrolment of
participants started before 2005: at that time this was neither
requested by National Authority nor was an established procedure
[19]. This has been done in retrospect at ClinicalTrials.gov
(Identifier: NCT02048215). The authors confirm that all ongoing
and related trials for this drug intervention are registered.
Patients and Study Design
This was a randomized double-blind, parallel group study.
Morbidly pre-menopausal obese female patients, non-smokers or
smoking less than 5 cigarettes per day, were selected from the
waiting list for bariatric surgery at Department of Surgery
(Molinette Hospital, Turin, Italy). In all patients the body weight
was stable during the three months before the study. To be eligible
for surgery the inclusion criteria were: BMI $40 kg/m2,
unresponsiveness to previous medically supervised weight loss
programs, and no major psychiatric disorders.
The exclusion criteria were: pregnancy, ischaemic heart disease,
cardiac failure, high blood pressure requiring drug treatment,
tachyarrhythmia, sick sinus syndrome, atrioventricular block, two-
bundle ventricular block, cerebrovascular diseases, occlusive
peripheral artery disease, renal failure, and current treatment
with drugs that might affect metabolic rate (e.g. b-adrenergic
blockers, thyroid hormones). According to previous studies about
the effect of the EC combination on thermogenesis in humans [20]
and rhesus monkeys [21], we expected a minimal difference in
resting metabolic rate (RMR) between treated and untreated
subjects not inferior to 17%, and mean to standard deviation ratio
not inferior to 10. Therefore, a minimum sample size of 12
subjects (6 in each treatment group) was considered adequate for a
power of 0.8 and alpha level of 0.05. Patients were randomised to
28-day treatment with either EC (200/20 mg ter in die [t.i.d.]) or
placebo. Allocation ratio was 1:1, with a block size of 4 (i.e. every
four patients two were allocated to EC and two to placebo).
Masking was double blind (subject, caregiver, investigator,
outcomes assessor). Randomisation lists was prepared – using
standard randomization number generation techniques – by the
statistics consultant of the Istituto Auxologico Italiano who had no
contact with patients. The randomization list was passed to the
Hospital Pharmacy which supplied the active compounds and
placebo, and which prepared sequentially numbered containers of
the study pills. The principal clinical investigator (MLP) enrolled
participants, and assigned participants to interventions. The EC
administration started with an initial dose of 100/10 mg ter in die,
for the first week and then proceeded with the full dose of 200/
20 mg t.i.d. In order to evaluate drug safety, the blood pressure
was measured three times a day; both electrocardiography and
echocardiography were recorded at baseline and every week. Body
weight was measured in a standardised manner at start and at the
end of treatment. During the treatment period all patients were fed
a hypocaloric diet (total energy content of ,70% of energy
expenditure, as measured by indirect calorimetry), and containing
20% proteins, 55% carbohydrates, 25% fat half of which was
monounsaturated, and 35 g/day fibres. They were hospitalised,
during the whole treatment period, at the metabolic unit of San
Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo
(Verbania, Italy). After diet and drug period, the patients were
transferred to the Department of Surgery (Molinette Hospital,
Turin) for the bariatric surgery. The drug treatment (EC and
placebo) was stopped the day before surgical intervention. Small
biopsies of rectus abdominis were taken during surgery, immedi-
ately frozen in liquid nitrogen, and stored at 280uC for
subsequent analysis.
Primary clinical outcome was the change in resting metabolic
rate (RMR), while the primary non-clinical outcome was the
UCP3 gene expression in skeletal muscle. Secondary outcomes
were changes in body weight and metabolic parameters (see
below), and drug safety.
Clinical Chemistry
After an overnight fast, blood was sampled to measure glucose,
insulin, free-fatty acids, glycerol, thyroid hormones, noradrenaline.
RMR was measured by indirect calorimetry. Plasma insulin levels
were measured by using a commercial enzymatic method (Tosoh,
Kyobashi Chuo-Ku, Tokio; Japan). Plasma samples for adrenaline
and noradrenaline levels were collected in refrigerated vials
containing EGTA and glutathione, stored at 280uC and
subsequently analysed by high-performance liquid chromatogra-
phy [22]. FFA were measured by an enzymatic assay (NEFA C,
Wako Chemicals GmbH, Japan). Glycerol was measured by a
spectrophotometric method [23]. All other determinations were
carried out by standard automated procedures. Homeostasis
model assessment (HOMA) was calculated as fasting plasma
glucose (mmol/l)/fasting plasma insulin (mU/l) [24].
Resting Metabolic Rate Measurement
Each subject, after an overnight fast (12–14 hours) and
30 minutes of resting, underwent RMR measurement: expired
gases were collected using a ventilated hood calorimeter (Sensor
Medics 2900, Anaheim, CA). The O2 and CO2 analysers were
calibrated before each test using gases of known O2 and CO2
concentration. Room temperature was maintained between 23uC
and 26uC throughout the study and all precautions were taken to
avoid any disturbing factors that could affect metabolic rate. The
RMR represents an average of the steady state (SS) periods. SS
was defined as a variation of not more 65% in VO2 and VCO2
Ephedrine/Caffeine, Muscle UCP3 and Morbid Obesity
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for at least 5 minutes. RMR was calculated with the Weir formula
[25].
Quantitative Polymerase Chain Reaction
Total RNA was isolated from skeletal muscle using the RNeasy
Lipid Tissue Kit (Qiagen, Milan, Italy). RNA was incubated with
DNase I and eluted in RNase-free water. The concentration of
RNA was determined by absorbance at 260 nm. Total RNA was
reverse transcribed (1 mg) using iScripTM cDNA Synthesis Kit
(Bio-Rad Laboratories, Italy). Specific sense and antisense primers
were designed using Beacon Designer 2.6 software from Premier
Biosoft International (Palo Alto, CA, USA) and synthesized by
PRIMM (Milan, Italy).
PCR was performed using the following primers: UCP3 short
form: sense primer GGACTATGGACGCCTACAGAAC, anti-
sense primer GGAAGTTGTCAGTGAGCAGGTG; UCP3 long
form: sense primer CCATCGCCAGGGAGGAAGG, antisense
primer GGAAGTTGTCAGTGAGCAGGTG; housekeeping
gene 18S: sense primer CTGCCCTATCAACTTTCGATGG-
TAG, antisense primer CCGTTTCTCAGGCTCCCTCTC.
Triplicate PCR reactions were carried out with the intercalating
dye SybrGreen. A melting curve was recorded at the end of PCR
to ensure the specificity of amplicons. Each sample (25 ml)
contained 12.5 ml iQTM SybrGreenI SuperMix (Bio-Rad),
0.4 mM each primer and 1/50 of reverse transcriptase product.
PCR cycles were programmed on an iCycler iQTM Real Time
PCR detection system (Bio-Rad). The cycle number at which the
various transcripts were detectable (CT) was compared to that of
18S, referred to as DCT. The gene relative level was expressed as
22(DDCT), in which DDCT equals DCT of the treated minus DCT
of the controls.
Statistical Analysis
In order to compare differences between the two treatment
groups at baseline Student’s t test for independent samples, and a
preliminary Kolmogorov-Smirnov test were performed on all the
biochemical and clinical parameters considered in the study. Since
we confirmed all data were distributed in a parametric fashion (p.
0.05 at Kolmogorov-Smirnov test), only paired or unpaired (as
adequate) Student’s t test was employed for analysing the data.
Comparison of outcomes between baseline and following the 28-
day treatment was carried out by Student’s t test for paired
samples. Statistical analysis was performed by Microsoft Excel and
SPSS software (SPSS Inc, Chicago, Illinois, USA).
Results
The flow diagram of patients’ enrollment and follow up is
reported in Figure 1. Out of eighteen patients screened, five were
excluded (all because of diabetes being diagnosed at baseline). We
studied 13 morbidly obese females, 36.3610.3 year-old (mean 6
SD; range 25–52 years) with body mass index (BMI) by
48.064.0 kg/m2 (mean 6 SD; ranging from 41.1 to 57.6 kg/
m2). All enrolled patients completed the study. No cardiovascular
side effects occurred over the study period. Three patients (one in
placebo and two in EC group) complained of insomnia after the
first week and were returned to half dosage for the entire treatment
period. Following the 28 day-treatment period, there was a
significant weight loss in both treatment groups vs. baseline
Figure 1. Flow diagram of patients’ enrollment and follow up.
doi:10.1371/journal.pone.0098244.g001
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(overall 25.263.2%, p,0.0001) as well as a reduction in BMI
value (Table 1), with no differences between the two groups. EC
increased the RMR (+9.266.8%, p= 0.020), whereas a significant
decrease of RMR was evident in the placebo group (27.666.5%,
p= 0.029) (Table 1). Patients receiving EC treatment showed a
mild increase in serum creatinine relative to placebo group, but in
none of patients this exceeded normal ranges. Circulating alanine
transaminase levels were slightly increased in the EC group
following treatment. There was no significant difference between
the two treatments in the other measured biochemical parameters
(Table 1).
Relative levels of UCP3S and UCP3L mRNAs were measured
by quantitative RT-PCR in the skeletal muscle samples. Figure 1
shows that no statistically significant changes of both short and
long UCP3 was evident between the two groups of patients.
Likewise, UCP3S/UCP3L mRNA ratio was not affected by the
EC treatment (Figure 2, inset). Thus, under our experimental
conditions the EC treatment was unable to change the muscle
UCP3 mRNA levels compared to placebo in morbidly obese
females.
Discussion
Because only a few small studies have been done in humans to
investigate the thermogenic effects of EC, in the present study we
examined the UCP3 expression in skeletal muscle of pre-
menopausal morbidly obese females treated with either placebo
or EC for 28 days. Our findings demonstrate that chronic
treatment with EC increased the RMR, in contrast with placebo
which decreased the RMR in obese patients. This result is
consistent with a previous study showing that the decrease in 24-
hour energy expenditure seen in the placebo group was 10% at
day 1 and 13% at day 56, but was only 7% and 8% in the EC-
treated group, and the weight-loss was not different in the two
groups after 8-week treatment [26]. On the other hand the results
from placebo controlled studies, conducted in different clinical
settings and in several countries, were highly consistent that EC is
an effective and well tolerated anti-obesity therapy [27–33].
Several reasons may justify this discrepancy. First, our is the only
study conducted in patients with very high grade obesity addressed
to bariatric surgery. Accordingly, one month may be a too short
treatment period to obtain relevant anti-obesity results, particu-
larly in patients with a massive obesity characterized by high
sympathetic activity [34,35]. In addition, our study was performed
in a small sample of patients, and this might have limited the
chance to observe the drug efficiency.
The reported increase of RMR after EC treatment may be due
to different physiological mechanisms, including an increased
energy expenditure through thermogenesis of brown adipose tissue
(BAT) and skeletal muscle [35]. At present, the recruitment in
BAT (i.e., the process including cell proliferation, mitochondrial
biogenesis, and increases in functional mitochondrial UCP1
content) is considered of great interest. This is because BAT is
now considered an active tissue even in adult humans [36], with
the capacity to oppose obesity or its development by burning some
of the energy we consume by feeding. In particular, human BAT
depots would be constituted mainly of beige/brite adipocytes [37],
expressing UCP1 when physiologically stimulated by cold or
drugs. Thus increasing proliferation and activation of these fat cells
might play a relevant role in obesity treatment. However, a more
appropriate reevaluation of these findings suggest that the relative
contribution of the beige/brite adipose tissue to the total
thermogenesis capacity, at least in animals, would be marginal
[38].
We focused our attention to the putative thermogesis activity of
skeletal muscle by investigating UCP3 expression in morbidly
obese females. We found no changes in UCP3S and UCP3L
isoform mRNAs in rectus abdominis of obese treated with EC in
comparison to obese patients treated with placebo. These results
Figure 2. UCP3 isoform mRNA levels in skeletal muscle of placebo- and EC-treated morbidly obese women. UCP3 long (UCP3L) and
short (UCP3S) mRNAs were measured by quantitative RT-PCR. mRNA levels were normalized to 18S RNA. n = 6 or 7 patients assigned to EC or to
placebo, respectively; error bars, s.d. The inset shows the UCP3S/UCP3L mRNA ratio. The PCR experiments were performed twice in triplicate. Data
were analysed by unpaired Student’s t test.
doi:10.1371/journal.pone.0098244.g002
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would suggest that muscle UCP3 is not directly linked to the
increased RMR induced by EC in obese subjects. A relevant
limitation of our study is that we could measure muscle UCP3
expression only as mRNA, but not as protein. Rephrasing the title
of a thoughtful review article by Nedergaard and Cannon [38]
‘‘UCP3 mRNA does not produce heat’’. On the other hand our
conclusion is supported by data obtained by Nabben et al. [15] in
skeletal muscle of UCP32/2 mice, and showing no evidence for
the function of UCP3 being basal or induced uncoupling.
Thus, how does EC treatment increase RMR value in obese
women? It has been shown that ephedrine stimulates brown
adipocyte respiration via b-adrenoceptors [39], and that the
thermogenic action of ephedrine can be enhanced by methylxan-
thines, such as caffeine, through their ability to inhibit the
phosphodiesterase-induced degradation of intracellular cyclic
AMP [40], and to antagonize the inhibitory action of adenosine
[41]. Anyway, several human studies have shown positive effects
on body-weight management of EC [42]. Besides activating b2-
adrenoceptors, EC treatment was found to enhance the b3-
adrenoceptor expression in white adipocytes of obese subjects,
following hypocaloric diet, when compared to placebo [43].
Together, those and our results allow to speculate that long-term
treatment with EC further increases the already high level of SNS
activity in morbidly obese patients. No significant changes in the
studied biochemical parameters were observed, and only a mild
increase in creatinine level, a reliable indicator to estimate skeletal
muscle mass status, was detected. We did not find any other
considerable variations, and the differences between the two
groups were not statistically significant. These data would
strengthen the safety profile of EC in morbid obesity, although
during the last years there have been raising safety concerns about
the use of ephedrine for pharmaceutical preparations, and the
combination (expecially in botanical formulations) was banned by
the U.S. Food and Drug Administration [44].
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